Hematology: Bortezomib and dexamethasone induction for multiple myeloma

Nature Reviews Clinical Oncology

Volumn 8, Issue 1, 2011, Pages 8-10

  Laubach, Jacob ^a   Richardson, Paul ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; MELPHALAN; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG FATALITY; DRUG TREATMENT FAILURE; EVENT FREE SURVIVAL; HLA MATCHING; HUMAN; INFECTION; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS, PHASE III AS TOPIC; DEXAMETHASONE; HUMANS; MULTIPLE MYELOMA; PYRAZINES; REMISSION INDUCTION;

EID: 78650531519     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.206     Document Type: Article

References (10)

1. Harousseau, J. L. et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the iFM 2005-01 phase iii trial. J. Clin. Oncol. 28, 4621-4629 (2010).
2. Lahuerta, J. J. et al. influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J. Clin. Oncol. 26, 5775-5782 (2008).
3. wang, M. et al. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant. 45, 498-504 (2010).
4. O'shea, D. et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant. 37, 731-737 (2006).
5. Majolino, i. et al. Autologous transplantation in multiple myeloma: a GiTMO retrospective analysis on 290 patients. Gruppo italiano Trapianti di Midollo Osseo. Haematologica 84, 844-852 (1999).
6. Cavo, M. et al. superior complete response rate and progression-free survival after autologous transplantation with up-front velcadethalidomide- dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood 112, a158 (2008).
7. Richardson, P. G. et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679-686 (2010).
8. McCarthy, P. L. et al. Phase iii intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): initial report of patient accrual and adverse events [abstract]. Blood 114, a3416 (2009).
9. Attal, M. et al. Lenalidomide after autologous transplantation for myeloma: first analysis of a prospective, randomized study of the intergroupe Francophone du Myelome (iFM 2005 02) [abstract]. Blood 114, a529 (2009).
10. Broyl, A. et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOvOn-65/GMMG-HD4 trial. Lancet Oncol. 11, 1057-1065 (2010).